CAR T‐cell therapy for pancreatic cancer

Chimeric antigen receptor (CAR) T‐cell therapy utilizes genetic engineering to redirect a patient's own T cells to target cancer cells. The remarkable results in hematological malignancies prompted investigating this approach in solid tumors such as pancreatic cancer. The complex tumor microenv...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of surgical oncology Vol. 116; no. 1; pp. 63 - 74
Main Authors:	DeSelm, Carl J., Tano, Zachary E., Varghese, Anna M., Adusumilli, Prasad S.
Format:	Journal Article
Language:	English
Published:	United States Wiley Subscription Services, Inc 01.07.2017
Subjects:	adoptive cell therapy Antigens, Neoplasm - immunology Cancer surgery CAR T cells Carcinoembryonic Antigen - immunology CD24 Antigen - immunology checkpoint blockade chimeric antigen receptor Clinical Trials as Topic GPI-Linked Proteins - immunology Humans immunotherapy Immunotherapy, Adoptive Mesothelin Mucin-1 - immunology Neoplasm Proteins - immunology Pancreatic cancer Pancreatic Neoplasms - immunology Pancreatic Neoplasms - therapy Receptor, ErbB-2 - immunology Receptors, Antigen, T-Cell Receptors, Natural Killer Cell - immunology Stromal Cells - immunology T-Lymphocytes - immunology T-Lymphocytes - transplantation Transplantation Conditioning checkpoint blockade chimeric antigen receptor CAR T cells adoptive cell therapy immunotherapy
ISSN:	0022-4790, 1096-9098, 1096-9098
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!